High Mobility Group Box-1: A Missing Link between Diabetes and Its Complications

Han Wu, Zheng Chen, Jun Xie, Li-Na Kang, Lian Wang, and Biao Xu

Department of Cardiology, Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China

Correspondence should be addressed to Lian Wang; wanglianglyy@163.com and Biao Xu; xubiao@medmail.com.cn

Received 20 May 2016; Accepted 3 October 2016

Academic Editor: Mirella Giovarelli

Copyright © 2016 Han Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

High mobility group box-1 (HMGB-1), a damage-associated molecular pattern, can be actively or passively released from various cells under different conditions and plays a pivotal role in the pathogenesis of inflammation and angiogenesis-dependent diseases. More and more evidence suggests that inflammation, in addition to its role in progression of diabetes, also promotes initiation and development of diabetic complications. In this review, we focus on the role of HMGB-1 in diabetes-related complications and the therapeutic strategies targeting HMGB-1 in diabetic complications.

1. Introduction

Diabetes is evolving as an epidemic disease, which affects about 400 million people worldwide. It is a metabolic disorder characterized by hyperglycemia due to defective insulin secretion or insulin resistance. Growing evidence on the involvement of inflammation in diabetes has made it an attractive topic. HMGB-1, an inflammatory mediator, can be released from various cells under different stress conditions. Over the past decade, a great gain of information about HMGB-1 in inflammatory diseases has been made. This review will give an overview of recent advances in HMGB-1 in diabetes, diabetic cardiovascular complications, diabetic nephropathy (DN), and diabetic retinopathy (DR), and then we will focus on therapeutic strategies targeting HMGB-1.

2. Introduction of HMGB-1

We will first introduce some definitions that will be used throughout the manuscript. These include ROS (reactive oxygen species), RAGE (receptor for advanced glycation end product), TLR2 (Toll-like receptor-2), TLR4 (Toll-like receptor-4), NF-κB (nuclear factor-κB), MyD88 (myeloid differentiation factor-88), p38MAPK (p38 mitogen-activated protein kinase), ERK (extracellular signal-regulated kinase), and JNK (c-Jun N-terminal kinase).

HMGB-1, a member of HMG protein superfamily, was first named 40 years ago because of its high mobility in polyacrylamide gel electrophoresis system [1, 2]. Human HMGB-1 is an about 30 kDa protein consisting of 215 amino acids and includes three distinct domains: two positive charged domains (A-box and B-box) composed of about 80 amino acids separately and a negatively charged acidic C-terminal tail composed of 30 amino acids. Furthermore, another 24 amino acids are used to link the domains [3]. HMG boxes A and B are able to mediate DNA binding, while the acidic C-tail can regulate the affinity of binding to distorted DNA structures via binding to other nuclear proteins [4] (Figure 1). HMGB-1 is a ubiquitous nuclear protein for maintaining DNA structure in various cells, but it can be actively or passively released under stress conditions. For example, in inflammation-associated immune cells such as monocytes and macrophages, HGMB-1 translocates from nuclear to special cytoplasmic organelles and is actively released outside the cells under stress. Besides, HMGB-1 may fail to bind to chromatin and is passively released into the extracellular space from cells undergoing necrosis, apoptosis, and injury [5]. However, secretion of HMGB-1 was recently shown to be negatively regulated by haptoglobin. Yang et al. found that haptoglobin-HMGB-1 complexes elicited anti-inflammatory cytokines in macrophages, suggesting a mechanism for haptoglobin modulation of HMGB-1 action [6] (Figure 1(a)).
Once it is released outside the cells, extracellular HMGB-1 functions as a multifunctional cytokine in many pathophysiological processes. There are several receptors for HGMB-1, but of importance are receptor for advanced glycation end product (RAGE), Toll-like receptor-2 (TLR2), and Toll-like receptor-4 (TLR4) [7]. By binding to its receptors, HMGB-1 induces nuclear translocation of activated nuclear factor-κB (NF-κB), leading to secretion of proinflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1 (IL-1) [8]. In addition, extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (p38MAPK), c-Jun N-terminal kinase (JNK), and myeloid differentiation factor-88 (MyD88) are also involved in HMGB-1-mediated signaling pathways [9–11], which finally contributes to immunoinflammatory response via proinflammatory cytokine secretion. It is worth mentioning that proinflammatory cytokines in turn promote more leakage of HMGB-1 from cells [12, 13], suggesting that HMGB-1-mediated signaling pathways are amplified by a positive feedback loop involving inflammation (Figure 1(b)).

### 3. HMGB-1 and Diabetes

In diabetic condition, HG or AGEs can induce HMGB-1 resection via oxidative stress. HMGB-1-RAGE interaction promotes islet cell apoptosis in diabetes by inducing oxidative stress, contributing to insulin deficiency. In addition, released HMGB-1 induces JNK/p38MAPK activation via binding to TLR4, which leads to insulin resistance via inhibitory phosphorylation of insulin receptor substrate. Finally, HMGB-1-induced insulin deficiency and insulin resistance contribute to the development of diabetes.

Additional definitions include HG (high glucose), AGEs (advanced glycation end products), ROS (reactive oxygen species), RAGE (receptor for advanced glycation end product), TLR4 (Toll-like receptor-4), JNK (c-Jun N-terminal kinase), p38MAPK (p38 mitogen-activated protein kinase), and IRS (insulin receptor substrate).

Diabetes has been widely recognized as a modern-day disease with a significant increase in morbidity and mortality worldwide. It is characterized as a chronic inflammation condition, and inflammatory mediators such as IL-1β, TNF-α, and IL-6 are increased in diabetes.

More and more evidence shows upregulation of IL-1β in serum and pancreatic islets from diabetes [14, 15]; furthermore, genetic or pharmacologic inhibition of IL-1β system has been shown to improve beta-cell function, insulin secretion, and glycemic control in proof-of-concept clinical studies and animal experiments [16–19]. Thus, the role of inflammation in diabetes has long been appreciated and gained broad attention [20].

It is demonstrated that subjects with diabetes exhibited higher serum HMGB-1 levels compared with nondiabetic patients [21]. Since then, the role of HMGB-1 in diabetes has been confirmed by other studies [22–24]. HMGB-1 was shown to be increased at the onset of cystic fibrosis-related diabetes [25] and was associated with indexes of glucose metabolism and body mass index in diabetes [24, 25]; however, treatment with insulin lowered its levels induced by glucose infusion [25, 26]. In addition, our recent work has also provided convincing evidence that type 1 diabetic mice exhibited markedly elevated serum HMGB-1 concentration compared with the controls [27].
Figure 2: Schematic representation of HMGB-1-mediated cellular signaling pathways in islet cells.

Furthermore, more and more in vitro experiments showed increased HMGB-1 expression in various cells upon exposure to high glucose [11, 28–30]. Wang et al. [30] demonstrated that high glucose induced HMGB-1 translocation through NADPH oxidase and PKC-dependent way in vascular smooth muscle cells. In diabetes, the elevated level of glucose promotes glycation of plasma proteins through a nonenzymatic process, which leads to advanced glycation end products (AGEs). AGEs contributed to metabolic memory effect as they exhibited their harmful effects for a long time via binding to RAGE even if the glucose was controlled well in diabetes. Recently, we found that HMGB-1 was upregulated in AGEs-induced endothelial progenitor cells (EPCs) via increased oxidative stress [27]. In line with our findings, another experiment showed that high-glucose-induced HMGB-1 expression in tubular epithelial cells was reduced by N-acetylcysteine (NAC), an antioxidant [11], suggesting that high glucose may lead to HMGB-1 expression via oxidative stress (Figure 2).

More and more studies showed a link between AGEs and HMGB-1 [31–33]. In vitro experiment has shown that AGEs induced endothelial dysfunction via HMGB-1-mediated inflammation and oxidative stress in human umbilical vein endothelial cells [34]. AGEs induced translocation and release of HMGB-1 from tubular epithelial cells; furthermore, HMGB-1 knockdown inhibited AGEs-induced expressions of cytokines, suggesting that HMGB-1 enhanced AGEs-induced expressions of cytokines. In addition, the effect of AGEs and HMGB-1 in epithelial cells was dependent on RAGE-mediated signaling pathway [35]. Thus, RAGE transduced the signals of AGEs and HMGB-1, and HMGB-1 amplified AGEs-mediated signaling pathways by binding to RAGE [36].

Islet beta-cell dysfunction and insulin resistance are two important pathogeneses of DM. Lee et al. [37] investigated the expression of RAGE in islet cells and the effect of HMGB-1 on islet cells. They surmised that HMGB-1–RAGE interaction contributed to islet cell apoptosis in type 2 diabetes by inducing oxidative stress. Activation of TLR4, another receptor of HMGB-1, activated proinflammatory kinases (such as p38MAPK and JNK) that impaired insulin signal transduction via inhibitory phosphorylation of insulin receptor substrate [38], suggesting the involvement of HMGB-1 in insulin resistance. In addition, pharmacological inhibition of TLR4 protected insulin resistance in fat-induced rats [39]. However, in contrast to these findings, another report showed that HMGB-1 promoted insulin secretion in islet beta-cells [40].

The discrepancy between the two results may be related to the cell lines and the exposure times to HMGB-1 used in the experiments. It is crucial to note that HMGB-1 may induce islet cells apoptosis and insulin resistance via binding to TLR4 and then contribute to initiation and development of DM (Figure 2).

Taken together, not only is HMGB-1 released in response to hyperglycemia via oxidative stress in diabetes, but also it contributes to the progression of diabetes via inducing islet cells apoptosis and insulin resistance, though the underlying mechanisms are not clearly understood.

4. HMGB-1 and Cardiovascular Complications

Cardiovascular complications including coronary artery disease and diabetic cardiomyopathy have become the leading causes of morbidity and mortality in diabetes. A growing body of evidence has indicated the important role of HMGB-1 in plaque formation, rupture, and thrombosis, which are all pathogenic phenomena in coronary artery disease. In addition, clinical studies showed elevated circulating HMGB-1 in coronary artery disease [21, 64, 65]. Higher level of HMGB-1 was reported to be associated with the severity of coronary artery stenosis and it may be a predictor for coronary atherosclerosis in young patients with chest pain and for cardiovascular mortality in acute coronary syndrome [64, 66–68]. As described in Table 1, increasing evidence has summarized the contribution of HMGB-1 to coronary artery disease with diabetes.

Two clinical studies showed significantly higher serum HMGB-1 level in coronary artery disease patients with diabetes than in patients without diabetes [21, 41]. Furthermore, a recent study reported that serum HMGB-1 was positively related to HbA1c level and was an independent predictor for coronary artery disease patients with diabetes [41].

Our recent study indicated that HMGB-1 could amplify oxidative stress in AGEs-induced endothelial progenitor cells, a subtype of CD34-positive cells [27]. In line with our studies, Feng and colleagues indicated that the interaction of HMGB-1 and its receptors triggered the oxidative stress in endothelial dysfunction [34]; similarly, serum HMGB-1 concentration was shown to reflect endothelial dysfunction in diabetes [22]. Recently, the increased HMGB-1 expression...
Mediators of Inflammation

Table 1: Functions of HMGB-1 in diabetic cardiovascular complications.

| Diseases/pathological phenomena | Involved signal molecule(s) | Notes | Ref. |
|---------------------------------|----------------------------|-------|------|
| CAD                             | HMGB-1                     | Elevated serum levels in diabetic patients with CAD. | [21] |
| CAD                             | HMGB-1                     | Serum HMGB-1 was increased in CAD patients with T2DM. | [41] |
| AMI                             | HMGB-1                     | HMGB-1 expression in thrombus was higher in AMI patients with DM and was positively correlated with blood glucose. | [42] |
| DCM                             | HMGB-1                     | Increased HMGB-1 expression in myocardial tissue of DCM. | [43] |
| DCM                             | HMGB-1, TGF-1beta, collagens, MMP2, MMP9, ERK, JNK, Akt | HMGB-1 promoted myocardial fibrosis and dysfunction in DCM. HMGB-1 mediated HG-induced TGF-1beta, collagens, and MMPs expressions in cardiac cells. Involvement of HMGB-1 in HG-induced cardiac fibroblasts proliferation and migration. | [44] |
| DCM                             | HMGB-1, RAGE               | HMGB-1/RAGE may be involved in HG-induced cardiomyocytes injury. | [45] |
| Foot atherogenesis               | HMGB-1, VCAM, NF-κB        | HMGB-1-induced inflammation mediated pathogenesis of diabetic foot atherogenesis. | [46] |
| I/R injury                      | HMGB-1, RAGE, NF-κB, TNF-α, IL-6 | HG induced inflammatory response via HMGB-1/RAGE/NF-κB pathway in I/R models. | [47] |
| Endothelial dysfunction         | HMGB-1, ROS                | HMGB-1 mediated ROS genesis in AGEs-induced EPCs. | [27] |
| Endothelial dysfunction         | Oxidative stress, HMGB-1, RAGE, ERK, NF-κB | HMGB-1 induced endothelial dysfunction via oxidative stress and RAGE/ERK/NF-κB pathway. | [34] |
| Endothelial dysfunction         | HMGB-1, RAGE, MMP9         | Serum HMGB-1 may reflect endothelial dysfunction developing in DM. | [22] |
| Cardiomyocyte apoptosis         | HMGB-1, ERK, Ets-1, caspase-3, Bax/Bcl-2 | HMGB-1 mediated hyperglycaemia-induced cardiomyocyte apoptosis. | [28] |

CAD: coronary artery disease; T2DM: type 2 diabetes mellitus; AMI: acute myocardial infarction; DM: diabetes mellitus; DCM: diabetic cardiomyopathy; TGF-1beta: transforming growth factor-1beta; MMP2: matrix metalloproteinase-2; MMP9: matrix metalloproteinase-9; ERK: extracellular signal-regulated kinase; JNK: c-Jun N-terminal kinase; HG: high glucose; RAGE: receptor for advanced glycation end product; VCAM: vascular cell adhesion molecule; NF-κB: nuclear factor-κB; I/R: ischemia-reperfusion; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; EPC: endothelial progenitor cell; ROS: reactive oxygen species; AGEs: advanced glycation end products; HUVEC: human umbilical vein endothelial cell; Bax/Bcl-2: ratio of Bcl-2-associated X protein to B-cell lymphoma/leukemia-2; Ets-1: E26 transformation-specific sequence-1; Ref.: references.

was found to be positively correlated with arterial stenosis, oxidative stress, and inflammation in diabetic patients with peripheral arterial occlusive disease [46]. In vitro experiment showed that microRNA-24 attenuated high-glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB-1. Furthermore, downregulation of HMGB-1 inhibited production of TNF-α and IL-6 via inhibition of NF-κB [52]. Yamashita and coworkers demonstrated that there were fewer CD34-positive cells and increased expression of HMGB-1 in acute coronary thrombi with DM [42]. In a thrombin-induced disseminated intravascular coagulation (DIC) rat model, HMGB-1 was shown to promote development of thrombosis [69]. The above evidence suggested that elevated HMGB-1 in diabetes induced oxidative stress, impaired endothelial repair, caused dysfunction of vascular smooth muscle and thrombosis, and finally led to ischemic event associated with diabetes.

Diabetic cardiomyopathy, a new diabetic complication independent of coronary artery disease and hypertension, has been increasingly recognized in diabetic patients by clinicians. More and more investigations indicated that HMGB-1 was diffusely expressed in myocardium of diabetic mice and in hyperglycaemia-induced cardiomyocytes [28, 43, 44]. Wang et al. [44] found that high glucose could induce HMGB-1 expression, translocation, and secretion in cardiomyocytes and fibroblasts. Similarly, HMGB-1 was reported to be upregulated in fibroblasts, macrophages, and cardiomyocytes isolated from diabetes mellitus subjects [47]. Besides that, a clinical study showed increased serum HMGB-1 in heart failure patients which was related to the severity of heart failure in diabetic patients [70]. Thus, there is a close link between HMGB-1 and heart failure. Wang and coworkers [44] reported that genetic inhibition of HMGB-1 improved myocardial function in diabetic cardiomyopathy, suggesting that HMGB-1 contributes to myocardial dysfunction in diabetes and inhibition of HMGB-1 might have therapeutic potential in treatment of diabetic cardiomyopathy.
Mechanistically, complex and highly diversified mechanisms are involved in the pathogenesis of diabetic cardiomyopathy, such as oxidative stress, inflammation, myocardial fibrosis, and apoptosis.

In a mice model of diabetic cardiomyopathy, HMGB-1 inhibition ameliorated left ventricular remodeling. In vitro, incubation of high glucose or HGMB-1 induced expression of collagens and profibrogenic factors, which were reversed by inhibition of HGMB-1 [44]. Recently, similar studies showed that HMGB-1 released from necrotic myocardial cells or active fibroblasts could induce fibroblast activation in vitro as well as myocardial fibrosis in vivo through TLR4-dependent signaling and ERK-dependent signaling pathway [71, 72].

Inflammation, another pathologic process in diabetic cardiomyopathy, was confirmed by increased expression of HMGB-1 in the ventricular myocardium as well as increased inflammatory cell infiltration and TNF-α expression. Interestingly, in vitro and in vivo experiments showed that hyperglycemia-induced HMGB-1 was reversed by treatment of resveratrol or metformin, both of which were considered as antioxidants [43, 45]. In addition, cultured cardiomyocytes showed increased cell death and HGMB-1 expression in response to H₂O₂ treatment [73]. These data indicated that the cross talk between oxidative stress and HMGB-1-mediated signaling pathway played an important role in diabetic cardiomyopathy.

5. HMGB-1 and DN (Diabetic Nephropathy)

DN has become one of the most devastating diabetic complications, the leading cause of end stage renal disease. HMGB-1 has been suggested to participate in inflammatory progress, contributing to the development and progression of DN (Table 2).

An increase of inflammatory factors including HMGB-1 was reported in DN [49, 74, 75]. In vitro, high glucose induced HMGB-1 and proinflammatory cytokines in renal mesangial cells and proximal tubular epithelial cells; furthermore, NF-κB mediated high-glucose-induced promotion of proinflammatory cytokines, suggesting that high glucose may induce HMGB-1 expression as well as inflammatory cytokines via activation of NF-κB signaling pathway [11, 48, 51].

One of the earliest investigations on the role of HMGB-1 in DN was prompted by the notion that HMGB-1 was a ligand of RAGE and TLRs in DN [49, 76]. In addition, upregulated HMGB-1 along with increased expressions of TLR2 and TLR4 in tubules was investigated in renal sections from DN patients [48, 49]. Indeed, the results were confirmed by in vitro studies that high glucose induced expressions of TLR2 and TLR4 and their downstream proteins in human proximal tubular epithelial cells, renal tubular epithelial cells, and podocytes [11, 48–50]. However, inhibition of TLR2 or TLR4 in diabetes exhibited reduced inflammatory responses [48, 50, 77], indicating that TLR2 or TLR4 might mediate HMGB-1-induced inflammation in DN.

In addition to inflammation, HMGB-1 and its receptors were also involved in fibrotic process of DN [35, 50, 77]. It has been established that RAGE activation promoted inflammation and fibrosis in DN [75, 78, 79]. Recently, an in vitro study showed that HMGB-1 enhanced the AGEs-induced expression of profibrogenic factors in renal tubular epithelial cells via RAGE-dependent signaling, suggesting that HMGB-1 may play an important role in the renal fibrotic process of DN via binding to RAGE [35]. Furthermore, elevated HMGB-1 along with increased interstitial fibrosis was reported in streptozotocin-induced DN; in contrast, marked reductions in interstitial fibrosis were evident in TLR4-deficient mice [50, 77]. Moreover, DN-induced MyD88 expression and NF-κB activity were significantly reversed in global TLR4-knockout mice [77]. An in vitro study showed that high glucose directly promoted TLR4 activation in podocytes and tubular epithelial cells and then resulted in NF-κB activation [50].

---

**Table 2: HMGB-1: evidence in DN (diabetic nephropathy).**

| Involved signal molecule(s) | Notes | Ref. |
|-----------------------------|-------|-----|
| HMGB-1, TLR4                | Strong HMGB-1 staining was detected in proximal and distal tubules of DN biopsies. | [48] |
| HMGB-1, TLR2, TLR4, MyD88, NF-κB | HMGB-1 and TLRs were upregulated in kidneys of diabetic rats, which were associated with increased renal expression of MyD88 and MCP-1 and activation of NF-κB. | [49] |
| HMGB-1, TLR4                | Upregulated expression of HMGB-1 and TLR4 in early diabetic kidney mice. | [50] |
| HMGB-1, TLR4, MyD88, SyK, NF-κB, TGF-β | ROS-dependent HMGB-1 expression led to Syk activation via binding to TLR4. | [11] |
| HMGB-1, NF-κB               | HMGB-1 mediated the D-glucose-induced proinflammatory cytokines in mesangial cells. | [51] |
| HMGB-1, RAGE, TLR4, CTGF, TGF-β | HMGB-1 enhanced AGE-induced expression of CTGF and TGF-β via RAGE and TLR4-dependent signaling. | [35] |
| HMGB-1, NF-κB, TNF-α, IL-6  | HMGB-1 was involved in high-glucose-induced vascular smooth muscle cell proliferation and migration. | [52] |

DN: diabetic nephropathy; TLR: Toll-like receptor; MyD88: myeloid differentiation factor-88; NF-κB: nuclear factor-κB; SyK: spleen tyrosine kinase; TGF-β: transforming growth factor-β; RAGE: receptor for advanced glycation end products; CTGF: connective tissue growth factor; AGE: advanced glycation end product; Ref.: references.
Thus, HMGB-1 may promote fibrosis and inflammation in diabetic kidney via its receptor including RAGE, TLR2, and TLR4; in addition, MyD88 and NF-κB may also be involved in this process.

6. HMGB-1 and DR (Diabetic Retinopathy)

DR is one of the most important complications of DM and is the leading cause of preventable blindness in working-age adults. From the first study demonstrating higher level of HMGB-1 in the vitreous from patients with DR [57] to recent work in a DR rat model suggesting that HMGB-1 expression in diabetic retina was significantly higher than in the control [62], the evidence points strongly to the role of HMGB-1 in different pathological processes of DR (Table 3).

Increasing evidence indicates that oxidative stress is a central regulator of HMGB-1’s activity in inflammation and cell death [61, 60]. In rat retinal ganglion cell line-5 (RGC-5 cell), AGEs stimulated release of HMGB-1 in cell supernatant as well as a significant increase of intracellular reactive oxygen species (ROS) production; however, NAC blocked HMGB-1 production via inhibition of oxidative stress [56]. Ethyl pyruvate, a well-known antioxidant substance, was shown to inhibit the upregulation of HMGB-1 in the retinas of oxygen-induced retinopathy [81]. The results indicated that HMGB-1 promoted development of DR via oxidative stress.

Inflammation has been considered as a contributing factor to the development of DR. HMGB-1, an alarm of inflammation, has also been reported to be upregulated in epiretinal membranes and vitreous fluid from DR [57, 58]. In vitro, AGEs or high glucose induced significant release of HMGB-1 from RGC-5 cells [56, 60]. Recently, cytoplasmic translocation of HMGB-1 was found in diabetes and high-glucose-induced retinal pericytes, which was dependent on RAGE/NF-κB pathway [59]. In a clinical study, levels of HMGB-1 were positively correlated with monocyte chemotactic protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1) in the vitreous fluid from patients with PDR, suggesting the role of HMGB-1 in inflammation of PDR [57].

HMGB-1 signaling pathway components including receptors for HMGB-1 and NF-κB were significantly upregulated in type 2 diabetic retinas and in high-glucose-treated retinal cells (acute retinal pigment epithelitis-19 cells (ARPE-19 cells) and RGC-5 cells) [29, 60]. Intravitreal administration of HMGB-1 or high-glucose-treated ARPE-19 cells induced significant upregulation of inflammatory signaling molecules, which was attenuated by inhibition of HMGB-1 [29, 58]. Furthermore, inhibition of HMGB-1 decreased expressions of TLR4 and NF-κB in high-glucose-induced RGC-5 cells [60]. These data suggested that diabetes-induced HMGB-1 possibly interacted with RAGE/TLR4 and activated ERK and NF-κB to generate an inflammatory response in DR.

In clinical investigations, the mean levels of HMGB-1 and angiogenesis biomarkers were significantly higher in PDR patients than in nondiabetic patients; furthermore, there was a positive correlation between vitreous fluid levels of HMGB-1 and sVE-cadherin, an angiogenesis biomarker [53, 55]. Incubation of human retinal microvascular endothelial cell (HRMEC) with HMGB-1 and intravitreal injection of HMGB-1 significantly increased expression of VEGF and VEGFR, both of which were shown to promote angiogenesis [54, 82]. In addition, AGEs-induced VEGF-A production in RGC-5 cells was suppressed by glycyrrhizin, an inhibitor of HMGB-1, suggesting that HMGB-1 was implicated in the angiogenesis of DR via regulating VEGF-A production [56, 82]. In line with the findings, a recent study demonstrated that HMGB-1 promoted lymphangiogenesis via TLR4/NF-κB/MMP9 signaling pathway, indicating that HMGB-1 may play an important role in diabetic retinopathy by modulating MMP9 [83].

Besides inflammation and angiogenesis, vascular permeability and neurodegeneration are also two important pathogeneses of DR. HMGB-1 reduced transendothelial electrical resistance of retinal endothelial cells in vitro and intravitreal administration of HMGB-1 to normal rats induced significantly increased retinal vascular permeability. In addition, diabetes induced upregulation of RAGE, ERK, and NF-κB; however, oral administration of glycyrrhizin, a specific inhibitor of HMGB-1, attenuated NF-κB activation. The results showed that HMGB-1 induced vascular barrier dysfunction via HMGB-1/RAGE/NF-κB signaling pathway [58].

Inverse correlation between serum levels of brain-derived neurotrophic factor (BDNF) and HMGB-1 was observed in proliferative diabetic retinopathy patients, and intravitreal administration of HMGB-1 induced decreased BDNF in rat retinas, suggesting that HGBM-1-induced downregulation of BDNF might be a therapeutic target to prevent DR neurodegeneration [61, 63]. Besides, HMGB-1 was found to promote neuropathy via regulating MMP9 [84, 85], which reveals a possible role for HMGB-1/MMP9 pathway in neurodegeneration during DR.

7. Therapeutic Strategies Targeting HMGB-1 in Diabetic Complications

Since HMGB-1 was involved in diabetes, some HMGB-1-targeted therapeutic strategies were found to intervene in diabetic complications.

Several hypoglycemic drugs have been considered as HMGB-1-targeted drugs in diabetes care. It has been demonstrated that insulin infusion suppressed HMGB-1/TLRs in monocytes of type 1 diabetes patients [26]. An in vitro experiment showed that metformin protected hyperglycemia-induced cardiomyocytes injury via inhibition of HMGB-1/RAGE expression [45].

Glycyrrhizin is a natural triterpene isolated in licorice and has been widely shown to protect against diabetic complications. Oral administration of glycyrrhizin protected retinal vascular barrier via inhibition of HMGB-1-mediated inflammatory signaling pathway in DR [58]. In addition, constant glycyrrhizin intake from the onset of diabetes significantly attenuated HMGB-1 expression and activated ERK1/2 in retina [86]. We previously found that glycyrrhizin inhibited HMGB-1 expression in AGEs-induced EPCs, indicating the possible effect of glycyrrhizin in EPCs dysfunction in diabetes [27].
### Table 3: HMGB-1 in DR (diabetic retinopathy).

| Pathological phenomenon(s) | Related signal molecule(s) | Notes | Ref. |
|-----------------------------|-----------------------------|-------|------|
| Angiogenesis                 | HMGB-1, VEGF, sVE-cadherin, sEng | HMGB-1, VEGF, sVE-cadherin, and sEng levels were higher in PDR patients than in nondiabetics. HMGB-1 was positively correlated with sVE-cadherin. | [53] |
| Angiogenesis                 | HMGB-1, RAGE, VEGF, CXCL12/CXCR4, HIF-α, early growth response-1, tyrosine kinase-2 | HMGB-1 induced upregulation of CXCL12/CXCR4, HIF-α, early growth response-1, and tyrosine kinase-2 in diabetic retinas. HMGB-1 induced VEGF and VEGFR2 expression in HRMEC. | [54] |
| Angiogenesis and fibrosis    | HMGB-1, OPN, CTGF | Upregulated HMGB-1 level in PDR and PVR patients compared with quiescent RD patients. | [55] |
| Neovascularization          | HMGB-1, VEGF-A | HMGB-1 mediated AGE-induced VEGF-A production in RGC-5 cells. | [56] |
| Inflammation, neovascularization, and hemorrhage | HMGB-1, MCP-1, sICAM-1 | HMGB-1 was related to neovascularization and hemorrhage in PDR patients. HMGB-1 expression was upregulated in the retinas of diabetic mice. | [57] |
| Inflammation and disrupted retinal vascular barrier | HMGB-1, RAGE, ERK, NF-κB, ICAM-1 | Increased expression of HMGB-1, RAGE, ERK, and NF-κB in diabetic retinas. HMGB-1 reduced transendothelial electrical resistance of bovine retinal endothelial cells. HMGB-1 induced upregulation of ICAM-1, sICAM-1, HMG-1, RAGE, ERK, and NF-κB and increased retinal vascular permeability. | [58] |
| Inflammation                | HMGB-1, RAGE, NF-κB | Cytoplasmic translocation of HMGB-1 in diabetes and high glucose in retinal pericytes. | [59] |
| Inflammation                | HMGB-1, NF-κB, TNF-α, VEGF | HMGB-1, receptors for HMGB-1, NF-κB, TNF-α, and VEGF were upregulated in diabetic retinas and HG-induced ARPE-19 cells. HMGB-1 blockage alleviated HG-induced expression of NF-κB and VEGF in ARPE-19 cells. | [29] |
| Apoptosis                   | HMGB-1, TLR4, NF-κB | Inhibition of HMGB-1 decreased expressions of TLR4 and NF-κB in high-glucose-induced RGC-5 cells. | [60] |
| Apoptosis                   | HMGB-1, NADPH oxidase, IL-1β, Nox2, PARP-1, caspase-3 | HMGB-1 and oxidative stress levels in vitreous fluid from PDR patients were higher than in controls. HMGB-1 was positively associated with oxidative stress level. HMGB-1 induced IL-1β, ROS, Nox2, PARP-1, and cleaved caspase-3 expressions in HRMEC and in the retinas of rats. | [61] |
| Apoptosis                   | HMGB-1, RAGE | HMGB-1/RAGE expressions as well as apoptosis cells in diabetic rat retina were higher than in controls. | [62] |
| Neurodegeneration            | HMGB-1, BDNF, TBARS, caspase-3, sRAGE, sICAM-1 | Decreased serum BDNF and increased serum HMGB-1, sRAGE, sICAM-1, and TBARS in PDR patients. HMGB-1 was negatively correlated with BDNF. HMGB-1 induced upregulation of TBARS and cleaved caspase-3 and downregulated expression of BDNF and synaptophysin in rat retinas. | [63] |

VEGF: vascular endothelial growth factor; sVE-cadherin: soluble vascular endothelial-cadherin; sEng: soluble endoglin; PVR: proliferative vitreoretinopathy; OPN: osteopontin; CTGF: connective tissue growth factor; RD: rhegmatogenous retinal detachment with no PVR; MCP-1: chemoattractant protein-1; sICAM-1: soluble intercellular adhesion molecule-1; BDNF: brain-derived neurotrophic factor; TBARS: thiobarbituric acid reactive substances; sRAGE: soluble receptor for advanced glycation end products; HRMEC: human retinal microvascular endothelial cell; IL-1β: interleukin-1β; Nox2: NADPH oxidase-2; PARP-1: poly(ADP-ribose) polymerase-1; NF-κB: nuclear factor-κB; ERK: extracellular signal-regulated kinase; HIF-α: hypoxia-inducible factor-1α; VEGFR2: vascular endothelial growth factor receptor-2; AGE: advanced glycation end product; RGC-5: retinal ganglion cell line 5; Ref.: references.
As mentioned above, oxidative stress was considered as an important player in regulating HMGB-1 in diabetes. Thus, antioxidant agents were shown to prevent diabetic complications via inhibition of HMGB-1. In diabetic mice, treatment with superoxide dismutase mimetic Mn(III)tetrakis(4-benzoic acid) porphyrin chloride (MnTBAP) normalized expression of HMGB-1/RAGE pathway [31]. Resveratrol, an antioxidant compound in red wine and vegetable foods, has been shown to prevent morpho-functional ventricular remodeling and attenuated HMGB-1 expression in type 1 diabetic rats [43]. Recently, we demonstrated that AGES-induced HMGB-1 expression was attenuated by treatment with NAC, a potent antioxidant [27].

Astilbin, a flavonoid compound found in Smilax china L., has been shown to protect against ischemia-reperfusion injury in diabetic rat heart via inhibition of HMGB-1/NF-κB signaling pathway [87]. Besides, several other agents such as ethyl pyruvate [81], quercetin [88–90], atorvastatin [91], and simvastatin [92] were explored in various diseases such as ethyl pyruvate [81], quercetin [88–90], atorvastatin [91], and simvastatin [92] were explored in various diseases. Currently, these studies have been focused on oxidative stress, HMGB-1 expression, and inflammation in diabetes. Thus, antioxidant compounds like astilbin, resveratrol, and NAC have the potential to be used as therapeutic agents in diabetes.

8. Conclusions

Diabetes induces HMGB-1 expression in various cells via oxidative stress; however, elevated HMGB-1 promoted initiation and development of diabetes via induction of insulin deficiency and insulin resistance. Furthermore, HMGB-1 mediated diabetic complications including CAD, DCM, DN, and DR via various signaling pathways. Though several drugs were shown to prevent diabetic complications via targeting HMGB-1, much further research is needed to explore novel HMGB-1-targeted therapeutics in diabetes care.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

The current study was supported by grants from the Natural Science Foundation of China (Grants nos. 81070195, 81200148, and 81270281), the Jiangsu Key Laboratory for Molecular Medicine of Nanjing University, Jiangsu Provincial Special Program of Medical Science (Grant no. BL2012014), the State Key Laboratory of Pharmaceutical Biotechnology (Grant no. KF-GN-200901), the Peak of Six Personnel in Jiangsu Province (Grant no. 2013-WSN-008), Funds for Distinguished Young Scientists in Nanjing (Grant no. JQX13006), and Natural Science Foundation of Jiangsu Province (Grant no. BK2010107).

References

[1] G. H. Goodwin, C. Sanders, and E. W. Johns, “A new group of chromatin-associated proteins with a high content of acidic and basic amino acids,” European Journal of Biochemistry, vol. 38, no. 1, pp. 14–19, 1973.

[2] G. H. Goodwin and E. W. Johns, “The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins,” Methods in Cell Biology, vol. 16, pp. 257–267, 1977.

[3] D. Musumeci, G. N. Roviello, and D. Montesarchio, “An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies,” Pharmacology and Therapeutics, vol. 141, no. 3, pp. 347–357, 2014.

[4] R. Kang, R. Chen, Q. Zhang et al., “HMGB1 in health and disease,” Molecular Aspects of Medicine, vol. 40, pp. 1–116, 2014.

[5] J. Cai, J. Wen, E. Bauer, H. Zhong, H. Yuan, and A. F. Chen, “The role of HMGB1 in cardiovascular biology: danger signals,” Antioxidants and Redox Signaling, vol. 23, no. 17, pp. 1351–1369, 2015.

[6] H. Yang, H. Wang, Y. A. Levine et al., “Identification of CD163 as an anti-inflammatory receptor for HMGB1-haptoglobin complexes,” JCI Insight, vol. 1, no. 7, 2016.

[7] J. R. van Beijnum, W. A. Buurman, and A. W. Griffioen, “Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1),” Angiogenesis, vol. 11, no. 1, pp. 91–99, 2008.

[8] F.-C. Wang, J.-X. Pei, J. Zhu et al., “Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro,” World Journal of Gastroenterology, vol. 21, no. 25, pp. 7764–7776, 2015.

[9] D. Zabini, S. Crnkovic, H. Xu et al., “High-mobility group box 1 induces vascular remodelling processes via c-Jun activation,” Journal of Cellular and Molecular Medicine, vol. 19, no. 5, pp. 1151–1161, 2015.

[10] S. Vogel, R. Bodenstein, Q. Chen et al., “Platelet-derived HMGB1 is a critical mediator of thrombosis,” Journal of Clinical Investigation, vol. 125, no. 12, pp. 4638–4654, 2015.

[11] W. S. Yang, J.-S. Kim, H. Lu et al., “IFN-γ-producing Th17 cells bias by HMGB1-T-bet/RUNX3 axis might contribute to progression of coronary artery atherosclerosis,” Atherosclerosis, vol. 243, no. 2, pp. 421–428, 2015.

[12] M. K. Gunasekaran, W. Viranaicken, A.-C. Girard et al., “Inflammation triggers high mobility group box 1 (HMGB1) secretion in adipose tissue, a potential link to obesity,” Cytokine, vol. 64, no. 1, pp. 103–111, 2013.

[13] G. Ozer, Z. Teker, S. Cetiner et al., “Serum IL-1, IL-2, TNFalpha and IFNgamma levels of patients with type 1 diabetes mellitus and their siblings,” Journal of Pediatric Endocrinology and Metabolism, vol. 16, no. 2, pp. 203–210, 2003.

[14] S. J. Richardson, A. Willcox, A. J. Bone, A. K. Foulis, and N. G. Morgan, “Islet-associated macrophages in type 2 diabetes,” Diabetologia, vol. 52, no. 8, pp. 1686–1688, 2009.

[15] C. Herder, E. Dalmas, M. Böni-Schnetzler, and M. Y. Donath, “The IL-1 pathway in type 2 diabetes and cardiovascular complications,” Trends in Endocrinology and Metabolism, vol. 26, no. 10, pp. 551–563, 2015.

[16] E. J. P. van Asseldonk, P. C. M. van Poppel, D. B. Ballak, R. Stienstra, M. G. Netea, and C. J. Tack, “One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with
type 1 diabetes mellitus,” *Clinical Immunology*, vol. 160, no. 2, pp. 155–162, 2015.

[18] H. E. Thomas, W. Irawaty, R. Darwiche et al., “IL-1 receptor deficiency slows progression to diabetes in the NOD mouse,” *Diabetes*, vol. 53, no. 1, pp. 113–121, 2004.

[19] J. Sloan-Lancaster, E. Abu-Raddad, J. Polzer et al., “Double-blind, randomized study evaluating the efficacy and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes,” *Diabetes Care*, vol. 36, no. 8, pp. 2239–2246, 2013.

[20] H. Khodabandeloo, S. Gorgani-Firuzjaee, G. Panahi, and R. Meshkani, “Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction,” *Translational Research*, vol. 167, no. 1, pp. 228–236, 2016.

[21] X. Yan, L. Lu, W. H. Peng et al., “Increased serum HMGB1 level is associated with coronary artery disease in non-diabetic and type 2 diabetic patients,” *Atherosclerosis*, vol. 205, no. 2, pp. 544–548, 2009.

[22] J. Škrha, M. Kalousová, J. Švarcová et al., “Relation of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus,” *Experimental and Clinical Endocrinology and Diabetes*, vol. 120, no. 5, pp. 277–281, 2012.

[23] M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, “Increased Toll-Like Receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects,” *Diabetes Care*, vol. 33, no. 4, pp. 861–868, 2010.

[24] H. Wang, H. Qu, and H. Deng, “Plasma HMGB-1 levels in subjects with obesity and type 2 diabetes: a cross-sectional study in China,” *PLoS ONE*, vol. 10, no. 8, Article ID e0136564, 2015.

[25] L. Montanini, F. Cirillo, A. Smerieri et al., “HMGB1 is increased by CFTR loss of function, is lowered by insulin, and increases in vivo at onset of CFRD,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 101, no. 3, pp. 1274–1281, 2016.

[26] P. Dandonia, H. Ghanim, K. Green et al., “Insulin infusion suppresses while glucose infusion induces toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 304, no. 8, pp. E810–E818, 2013.

[27] H. Wu, R. Li, Z.-H. Wei et al., “Diabetes-induced oxidative stress in endothelial progenitor cells may be sustained by a positive feedback loop involving high mobility group box 1,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 1943918, 9 pages, 2016.

[28] W.-K. Wang, Q.-H. Lu, J.-N. Zhang et al., “HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway,” *Journal of Cellular and Molecular Medicine*, vol. 18, no. 11, pp. 2311–2320, 2014.

[29] X.-L. Chen, X.-D. Zhang, Y.-Y. Li, X.-M. Chen, D.-R. Tang, and R.-J. Ran, “Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: evidence from type 2 diabetic rats and ARPE-19 cells under diabetic condition,” *British Journal of Ophthalmology*, vol. 97, no. 12, pp. 1598–1603, 2013.

[30] Y. Wang, J. Shan, W. Yang, H. Zheng, and S. Xue, “High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins,” *Inflammation*, vol. 36, no. 6, pp. 1592–1604, 2013.

[31] D. Yao and M. Brownlee, “Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands,” *Diabetes*, vol. 59, no. 1, pp. 249–255, 2010.

[32] A. Soro-Paavonen, A. M. D. Watson, J. Li et al., “Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes,” *Diabetes*, vol. 57, no. 9, pp. 2461–2469, 2008.

[33] C. Kouli, J. B. De Haan, and T. J. Allen, “Novel pathways and therapies in experimental diabetic atherosclerosis,” *Expert Review of Cardiovascular Therapy*, vol. 10, no. 3, pp. 323–335, 2012.

[34] L. Feng, M. Zhu, M. Zhang et al., “Amelioration of compound 4,4′-diphenylmethane-bis(methyl)carbamate on high mobility group box-1-mediated inflammation and oxidant stress responses in human umbilical vein endothelial cells via RAGE/ERK1/2/NF-kB pathway,” *International Immunopharmacology*, vol. 15, no. 2, pp. 206–216, 2013.

[35] M. Cheng, H. Liu, D. Zhang et al., “HMGB1 enhances the AGER-induced expression of CTGF and TGF-β via RAGE-dependent signaling in renal tubular epithelial cells,” *American Journal of Nephrology*, vol. 41, no. 3, pp. 257–266, 2015.

[36] K. Fukami, S.-I. Yamagishi, and S. Okuda, “Role of AGERs-RAGE system in cardiovascular disease,” *Current Pharmaceutical Design*, vol. 20, no. 14, pp. 2395–2402, 2014.

[37] B.-W. Lee, H. Y. Chae, S. J. Kwon, S. Y. Park, J. Ihm, and S.-H. Ihm, “RAGE ligands induce apoptotic cell death of pancreatic beta-cells via oxidative stress,” *International Journal of Molecular Medicine*, vol. 26, no. 6, pp. 813–818, 2010.

[38] J. J. Kim and D. D. Sears, “TLR4 and insulin resistance,” *Gastroenterology Research and Practice*, vol. 2010, Article ID 212563, 11 pages, 2010.

[39] N. Zhang, H. Liang, R. V. Farese, J. Li, N. Musi, and S. E. Huskey, “Pharmacological TLR4 inhibition protects against acute and chronic fat-induced insulin resistance in rats,” *PLoS ONE*, vol. 10, no. 7, Article ID e0132575, 2015.

[40] R. Guzmán-Ruiz, F. Ortega, A. Rodriguez et al., “Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells,” *International Journal of Obesity*, vol. 38, no. 12, pp. 1545–1554, 2014.

[41] D. Zhao, Y. Wang, K. Tang, and Y. Xu, “Increased serum HMGB1 related with HbA1c in coronary artery disease with type 2 diabetes mellitus,” *International Journal of Cardiology*, vol. 168, no. 2, pp. 1559–1560, 2013.

[42] A. Yamashita, K. Nishihira, Y. Matsuura et al., “Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus,” *Atherosclerosis*, vol. 224, no. 2, pp. 511–514, 2012.

[43] F. Delucchi, R. Berni, C. Fritti et al., “Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats,” *PLoS ONE*, vol. 7, no. 6, article e39836, 2012.

[44] W.-K. Wang, B. Wang, Q.-H. Lu et al., “Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy,” *International Journal of Cardiology*, vol. 172, no. 1, pp. 202–212, 2014.

[45] T. Zhang, X. Hu, Y. Cai, B. Yi, and Z. Wen, “Metformin protects against hyperglycemia-induced cardiomyocytes injury by
inhibiting the expression of receptor for advanced glycation end products and high mobility group box 1 protein,” *Molecular Biology Reports*, vol. 41, no. 3, pp. 1335–1340, 2014.

[46] C. F. Tsao, W. T. Huang, T. T. Liu et al., “Expression of high-mobility group box protein 1 in diabetic foot Atherosclerosis,” *Genetics and Molecular Research*, vol. 14, no. 2, pp. 4521–4531, 2015.

[47] H. C. Volz, C. Seidel, D. Laohachewin et al., “HMGB1: the missing link between diabetes mellitus and heart failure,” *Basic Research in Cardiology*, vol. 105, no. 6, pp. 805–820, 2010.

[48] M. Lin, W. H. Yiu, H. J. Wu et al., “Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy,” *Journal of the American Society of Nephrology*, vol. 23, no. 1, pp. 86–102, 2012.

[49] F. Li, N. Yang, L. Zhang et al., “Increased expression of toll-like receptor 2 in rat diabetic nephropathy,” *American Journal of Nephrology*, vol. 32, no. 2, pp. 179–186, 2010.

[50] J. Ma, S. J. Chadban, C. Y. Zhao et al., “TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy,” *PLoS ONE*, vol. 9, no. 5, Article ID e97985, 2014.

[51] Y. Chen, F. Qiao, Y. Zhao, Y. Wang, and G. Liu, “HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose,” *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 6, pp. 6683–6691, 2015.

[52] J. Yang, L. Chen, J. Ding et al., “MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1,” *Gene*, vol. 586, no. 2, pp. 268–273, 2016.

[53] A. M. Abu El-Asrar, M. I. Nawaz, D. Kangave, M. Abouamnog, and G. Mohammad, “High-mobility group box 1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy,” *Mediators of Inflammation*, vol. 2012, Article ID 697489, 7 pages, 2012.

[54] A. M. A. El-Asrar, G. Mohammad, M. I. Nawaz, and M. M. Siddiquei, “High-mobility group box 1 modulates the expression of inflammatory and angiogenic signaling pathways in diabetic retina,” *Current Eye Research*, vol. 40, no. 11, pp. 1141–1152, 2015.

[55] A. M. Abu El-Asrar, M. Imtiaz Nawaz, D. Kangave, M. M. Siddiquei, and K. Geboes, “Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders,” *Mediators of Inflammation*, vol. 2012, Article ID 493043, 8 pages, 2012.

[56] J.-J. Lee, C.-C. Hsiao, I.-H. Yang et al., “High-mobility group box 1 protein is implicated in advanced glycation end-products-induced vascular endothelial growth factor production in the rat retinal ganglion cell line RGC-5,” *Molecular Vision*, vol. 18, pp. 838–850, 2012.

[57] A. M. A. El-Asrar, M. I. Nawaz, D. Kangave et al., “High-mobility group box 1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy,” *Molecular Vision*, vol. 17, pp. 1829–1838, 2011.

[58] G. Mohammad, M. M. Siddiquei, A. Othman, M. Al-Shabrawey, and A. M. Abu El-Asrar, “High-mobility group box 1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina,” *Experimental Eye Research*, vol. 107, pp. 101–109, 2013.

[59] J. Kim, C. S. Kim, E. Sohn et al., “Cytoplasmic translocation of high-mobility group box 1 protein is induced by diabetes and high glucose in retinal pericytes,” *Molecular Medicine Reports*, vol. 14, no. 4, pp. 3655–3661, 2016.

[60] H. Zhao, J. Zhang, and J. Yu, “HMGB-1 as a potential target for the treatment of diabetic retinopathy,” *Medical Science Monitor*, vol. 21, pp. 3062–3067, 2015.

[61] G. Mohammad, K. Alam, M. I. Nawaz, M. M. Siddiquei, A. Mousa, and A. M. Abu El-Asrar, “Mutual enhancement between high-mobility group box-1 and NADPH oxidase-derived reactive oxygen species mediates diabetes-induced upregulation of retinal apoptotic markers,” *Journal of Physiology and Biochemistry*, vol. 71, no. 3, pp. 359–372, 2015.

[62] Y. Yu, L. Yang, J. Lv et al., “The role of high mobility group box 1 (HMGB-1) in the diabetic retinopathy inflammation and apoptosis,” *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 6, pp. 6807–6813, 2015.

[63] A. M. Abu El-Asrar, M. I. Nawaz, M. M. Siddiquei, A. S. Al-Kharashi, D. Kangave, and G. Mohammad, “High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina,” *Mediators of Inflammation*, vol. 2013, Article ID 863036, 11 pages, 2013.

[64] T. Hashimoto, J. Ishii, F. Kitagawa et al., “Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction,” *Atherosclerosis*, vol. 221, no. 2, pp. 490–495, 2012.

[65] M. Andrassy, H. C. Volz, A. Schuessler et al., “HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease,” *PLoS ONE*, vol. 7, no. 12, Article ID e52081, 2012.

[66] S. Haghi-Javanimard, M. Sadeghi, S. Safavi, M. Gheraati, and N. Dana, “Prognostic value of the high-mobility group box 1 in young patients with chest pain,” *Arq Atherosclerosis*, vol. 10, no. 3, pp. 154–158, 2014.

[67] K. Peter and A. Bobik, “HMGB1 signals danger in acute coronary syndrome: emergence of a new risk marker for cardiovascular death?” *Atherosclerosis*, vol. 221, no. 2, pp. 317–318, 2012.

[68] J. W. M. Nin, I. Ferreira, C. G. Schalkwijk et al., “Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 Year Follow-up Study,” *Diabetologia*, vol. 55, no. 9, pp. 2489–2493, 2012.

[69] T. Ito, K. Kawahara, T. Nakamura et al., “High-mobility group box 1 protein promotes development of microvascular thrombosis in rats,” *Journal of Thrombosis and Haemostasis*, vol. 5, no. 1, pp. 109–116, 2007.

[70] L. J. Wang, L. Lu, F. R. Zhang, Q. J. Chen, R. De Caterina, and W. F. Shen, “Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure,” *European Journal of Heart Failure*, vol. 13, no. 4, pp. 440–449, 2011.

[71] W. Zhang, K. J. Lavine, S. Epelman et al., “Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo,” *Journal of the American Heart Association*, vol. 4, no. 6, Article ID e001993, 2015.

[72] Z. Su, J. Yin, T. Wang et al., “Up-regulated HMGB1 in EAM directly led to collagen deposition by a PKCδ/Erk1/2-dependent pathway: cardiac fibroblast/myofibroblast might be another
source of HMGB1," *Journal of Cellular and Molecular Medicine*, vol. 18, no. 9, pp. 1740–1751, 2014.

[73] Y. Yu, M. Liu, L. Zhang et al., "Heat shock transcription factor 1 inhibits H2O2-induced cardiomyocyte death through suppression of high-mobility group box 1," *Molecular and Cellular Biochemistry*, vol. 364, no. 1-2, pp. 263–269, 2012.

[74] P. Palsamy and S. Subramanian, "Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling," *Biochimica et Biophysica Acta- Molecular Basis of Disease*, vol. 1812, no. 7, pp. 719–731, 2011.

[75] J. Kim, E. Sohn, C.-S. Kim, K. Jo, and J. S. Kim, "The role of high-mobility group box-1 protein in the development of diabetic nephropathy," *American Journal of Nephrology*, vol. 33, no. 6, pp. 524–529, 2011.

[76] S. A. Penfold, M. T. Coughlan, S. K. Patel et al., "Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy," *Kidney International*, vol. 78, no. 3, pp. 287–295, 2010.

[77] I. Jialal, A. M. Major, and S. Devaraj, "Global toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy," *Journal of Diabetes and its Complications*, vol. 28, no. 6, pp. 755–761, 2014.

[78] M. D. Oldfield, L. A. Bach, J. M. Forbes et al., "Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)," *Journal of Clinical Investigation*, vol. 108, no. 12, pp. 1853–1863, 2001.

[79] K. C. Sourris, A. L. Morley, A. Koitka et al., "Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor," *Diabetologia*, vol. 53, no. II, pp. 2442–2451, 2010.

[80] Y. Yu, D. Tang, and R. Kang, "Oxidative stress-mediated HMGB1 biology," *Frontiers in Physiology*, vol. 6, article 93, 2015.

[81] Y. M. Lee, J. Kim, K. Jo et al., "Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression," *Journal of Diabetes Research*, vol. 2013, Article ID 245271, 8 pages, 2013.

[82] G. Mohammad, D. Jomar, M. M. Siddiquei, K. Alam, and A. M. Abu El-Asrar, "High-mobility group box-1 protein mediates the regulation of signal transducer and activator of transcription-3 in the diabetic retina and in human retinal Muller cells," *Ophthalmic Research*, 2016.

[83] L. Han, M. Zhang, M. Wang et al., "High mobility group box-1 promotes inflammation-induced lymphangiogenesis via toll-like receptor 4-dependent signalling pathway," *PLoS ONE*, vol. 11, no. 4, Article ID e0154187, 2016.

[84] F. F. Zhang, N. Morioka, S. Harano et al., "Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloprotease-9 up-regulation in mice with painful peripheral neuropathy," *Journal of Neurochemistry*, vol. 136, no. 4, pp. 837–850, 2016.

[85] F. L. Cardoso, J. Herz, A. Fernandes et al., "Systemic inflammation in early neonatal mice induces transient and lasting neurodegenerative effects," *Journal of Neuroinflammation*, vol. 12, article 82, 2015.

[86] A. M. Abu El-Asrar, M. M. Siddiquei, M. I. Nawaz, K. Geboes, and G. Mohammad, "The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes," *Mediators of Inflammation*, vol. 2014, Article ID 746415, 10 pages, 2014.

[87] H. Diao, Z. Kang, F. Han, and W. Jiang, "Aristolin protects diabetic rat heart against ischemia-reperfusion injury via blockade of HMGB1-dependent NF-κB signaling pathway," *Food and Chemical Toxicology*, vol. 63, pp. 104–110, 2014.

[88] S. S. Dhumale, B. N. Waghela, and C. Pathak, "Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells," *IUBMB Life*, vol. 67, no. 5, pp. 361–373, 2015.

[89] V. Karuppagounder, S. Arumugam, R. A. Thandavarayan et al., "Modulation of HMGB1 translocation and RAGE/NFkB cascade by quercetin treatment mitigates atopic dermatitis in NC/Nga transgenic mice," *Experimental Dermatology*, vol. 24, no. 6, pp. 418–423, 2015.

[90] D. Tang, R. Kang, W. Xiao et al., "Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function," *American Journal of Respiratory Cell and Molecular Biology*, vol. 41, no. 6, pp. 651–660, 2009.

[91] L. Wang, X. Zhang, L. Liu, R. Yang, L. Cui, and M. Li, "Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-κB expression," *Neuroscience Letters*, vol. 471, no. 3, pp. 152–156, 2010.

[92] M. Liu, Y. Yu, H. Jiang et al., "Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE-/- mice by downregulating the HMGB1-RAGE axis," *Acta Pharmacologica Sinica*, vol. 34, no. 6, pp. 830–836, 2013.